Project description
Stomach cancer meets its match in a photoactivated oral capsule
The discovery in 2005 that almost all cases of peptic ulcer disease were caused by a previously unknown bacterial species, Helicobacter pylori, garnered the Nobel Prize in Physiology or Medicine the same year. We now know that this bacterium is also responsible for most gastric cancers, and it is very difficult to eliminate with antibiotics. The EU-funded Capsulight project is supporting the Italian SME PROBIOMEDICA in developing a pioneering patented therapy that relies on an oral capsule and its activation by light. Compared to antibiotics' 70 % efficacy, preliminary results suggest that it is almost 100 % effective at killing the bacteria; therefore, it could be the solution that will stop stomach cancer in its tracks.
Objective
Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in some European Countries. Once it is diagnosed, it has to be eradicated, since it is a carcinogen agent and around 90% of all gastric cancers can be attributable to its infection. The only available treatment is a pharmacological therapy based on the assumption of proton-pump inhibitor and a mix of 2-3 antibiotic drugs. Unfortunately, due to increasing antibiotic resistance, up to 30% of the affected population cannot be cured, despite several cycles of antibiotic therapy and usually endoscopic biopsy to determine antibiotic-resistance. Probiomedica is a spin-off of the University of Florence and Scuola Superiore Sant’Anna specialized in photobiology and robotics applied to medicine, which has developed and patented CapsuLight, the first ingestible capsule able to eradicate H. Pylori infection through intragastric photodynamic therapy, that is through the power of light. The device is based on the established technology and safety of endoscopic capsules for diagnostic use, and our preliminary in vitro tests showed 97% efficacy in killing the bacterium. The advantages for infected population are unparalleled: the possibility to eradicate the bacterium for those who cannot be cured due to antibiotic resistance (our first target market); the higher efficacy rate, no side effects due to antibiotic cycles, and easy posology for all the infected population (secondary market). CapsuLight will also provide high economic savings to National Healthcare Systems, by reducing drug therapies cycles and endoscopic biopsies and related costs for hospitalization. Probiomedica has already presented the product to several gastroenterology and microbiology centers and will optimize the capsule design for further miniaturization and mass production, and to undergo the necessary clinical validation for getting the CE mark during the Phase 2 project.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
- medical and health sciences basic medicine physiology homeostasis
- medical and health sciences clinical medicine gastroenterology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
50124 FIRENZE
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.